Clinical communication to the Editor
Monotherapy with Ezetimibe Causing Myopathy

https://doi.org/10.1016/j.amjmed.2005.06.051Get rights and content

References (4)

There are more references available in the full text version of this article.

Cited by (37)

  • Is it really myositis? Mimics and pitfalls

    2022, Best Practice and Research: Clinical Rheumatology
  • Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia

    2016, American Heart Journal
    Citation Excerpt :

    In one case report, a patient with a history of a history of statin-associated exercise-induced muscle pain developed muscle symptoms again when treated alone with ezetimibe. Her symptoms promptly resolved after stopping ezetimibe.19 Similarly, in another report, a patient with dyslipidemia, a strong family history of CHD, Raynaud's phenomenon, and statin-associated muscle symptoms who was symptom-free after stopping statin developed muscle symptoms again after only 2 weeks of ezetimibe therapy.20

  • Iatrogenic neurology

    2014, Handbook of Clinical Neurology
  • Drugs Causing Muscle Disease

    2011, Rheumatic Disease Clinics of North America
    Citation Excerpt :

    The most prevalent drug-induced myopathies are those caused by lipid-lowering agents. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), fibric acid derivatives (fibrates), niacin, and ezetimibe may all cause myopathy in some patients.1,2 However, it should be noted that the high prevalence of myotoxicities associated with these agents is not because of a large risk from their use but rather because the use of such drugs is extremely common.3

  • Drugs that affect lipid metabolism

    2010, Side Effects of Drugs Annual
  • Neurotoxic Effects of Pharmaceutical Agents V: Miscellaneous Agents

    2009, Clinical Neurotoxicology: Syndromes, Substances, Environments, Expert Consult - Online and Print
View all citing articles on Scopus
View full text